Genor Biopharma Holdings Ltd. has provided a monthly update on its proposed merger involving the issuance of consideration shares under a specific mandate. This update follows a series of announcements related to the transaction, including the proposed merger, new listing application, and other related plans. The company highlighted that if certain conditions are not met, the merger agreement will not proceed. The announcement was made by Weng Chengyi, the Executive Director and Chief Financial Officer of Genor Biopharma Holdings Ltd., on June 13, 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。